The short version of Mod GRF(1-29) fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-28. Anything still debated is marked as such rather than presented as settled.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
Meanwhile the affected person undergoes myeloablative conditioning, after which the altered HSCs can be infused back, becoming engrafted in the bone marrow where they proliferate. This results in a progressive increase in beta-globin synthesis which improves the balance of alpha and beta globins in all subsequent developing red blood cells. Healthy hemoglobin A is generated resolving the anemia. Exagamglogene autotemcel, sold under the brand name Casgevy, is a gene therapy for the treatment of transfusion-dependent beta thalassemia which induces increased production of fetal hemoglobin HbF. The treatment was approved in the United Kingdom for the treatment of transfusion-dependent beta thalassemia in November 2023 and in the United States in January 2024. Casgevy works by editing the BCL11A gene, which normally inhibits the production of HbF in adults. The edit has the effect of increasing production of gamma globin, a component of fetal hemoglobin HbF, and thereby resolving the anemia.
=== Wet symptoms === Circulatory shock Diarrhea (feces which resemble more liquid than solid) Hemorrhage (bleeding) and sometimes bleeding diathesis (a person loses more blood than usual from an injury – for example, getting only a little cut, and losing a lot of blood) Petechiae (small red or purple spots) Swelling caused by edema The severity of symptoms varies with both individual immune competence and the type of virus. The "VHF syndrome" causes bleeding diathesis, capillary leak, and circulatory shock. It happens to most people who have Filoviridae infections (such as Ebola virus or Marburg virus), Crimean–Congo hemorrhagic fever (CCHF), or the South American hemorrhagic fevers (which are caused by Arenaviridae). VHF syndrome only happens to a small minority of people who have dengue fever or Rift Valley fever.
=== Hitler government and new elections === Meanwhile, Papen had formed an intrigue to oust his successor. He conferred with Hugenberg and industrial magnates and bankers during a feverish night in which the outcome was unclear to all participants. On 30 January 1933 Hitler was appointed Chancellor with Papen as Vice-Chancellor and Hugenberg as minister for economics. Though seeing their adversaries Papen and Hugenberg join forces with Hitler, the Centre Party still did not give up building a broad coalition government. Since the new administration was still lacking a majority in parliament, the Centre was ready to support it, either by toleration or by coalition. Hitler intended to minimise non-Nazi participation, but feigned a willingness to cooperate with the Centre and blamed Papen and Hugenberg for denying cabinet posts to the Centre. When Kaas requested a broad outline of his government's objectives, Hitler used the questionnaire presented by Kaas to declare the talks a failure and obtain the President's approval for calling for new elections for the third time in about half a year. These elections in March 1933 were already marred by the SA's terror, after the Reichstag fire and civil rights had been suspended by President Hindenburg through the Reichstag Fire Decree. Still the Centre Party campaigned hard against the Hitler administration and managed to preserve their former vote of roughly 11 per cent. The government parties NSDAP and DNVP however jointly won 52 per cent of the vote.
Sources: en.wikipedia.org
=== Low affinity receptors === The other NT-3 receptor, the LNGFR, plays a somewhat less clear role. Some researchers have shown the LNGFR binds and serves as a "sink" for neurotrophins. The crystal structure of NT-3 shows that NT-3 forms a central homodimer around which two glycosylated p75 LNGFR molecules bind symmetrically. The symmetrical binding takes place along the NT-3 interfaces, resulting in a 2:2 ligand-receptor cluster in the center. Cells which express both the LNGFR and the Trk receptors might therefore have a greater activity – since they have a higher "microconcentration" of the neurotrophin. It has also been shown, however, that the LNGFR may signal a cell to die via apoptosis – so therefore cells expressing the LNGFR in the absence of Trk receptors may die rather than live in the presence of a neurotrophin.
Racetams, such as piracetam, oxiracetam, phenylpiracetam, and aniracetam, are often marketed as cognitive enhancers and sold over the counter. A 2019 study found that piracetam supplements sold in the United States were inaccurately labeled. Racetams are often referred to as nootropics, but this property is not well established in humans, and nootropics are not consistently found in all racetams. The racetams have poorly understood mechanisms, although piracetam and aniracetam are known to act as positive allosteric modulators of AMPA receptors and appear to modulate cholinergic systems. Similar compounds, such as noopept and aloracetam, do not meet the chemical definition for being a racetam, though they are considered "racetam-like" due to their high similarity. According to the FDA,
The FDA has identified that breast implants may be associated with a rare form of cancer called anaplastic large-cell lymphoma (ALCL), which some experts believe is believed to be associated with chronic bacterial inflammation. Similar ALCL phenomena have been seen with other types of medical implants including vascular access ports, orthopedic hip implants, and jaw (TMJ) implants. The causal association between breast implants and ALCL was conclusively established in December 2013, when researchers at MD Anderson Cancer Center published a study of 60 women with breast implants who were diagnosed with ALCL in the breast. In 2015, plastic surgeons published an article reviewing 37 articles in the literature on 79 patients and collected another 94 unreported cases, resulting in 173 women with breast implants who had developed ALCL of the breast. They concluded that "Breast implant-associated ALCL is a novel manifestation of site- and material-specific lymphoma originating in a specific scar location, presenting a wide array of diverse characteristics and suggesting a multifactorial cause." They stated that "There was no preference for saline or silicone fill or for cosmetic or reconstructive indications." Where implant history was known, the patient had received at least one textured-surface device. In 2016, the World Health Organization (WHO) officially recognized BIA-ALCL. As of April 2022, the FDA has received 1,130 global medical device reports (MDRs) of BIA-ALCL, including 59 deaths.
Cleavage takes place in two steps: first, the 3’,5’-phosphodiester bond is cleaved to generate a 2’,3’-cyclic phosphodiester intermediate; second, the cyclic phosphodiester is hydrolyzed to a 3’-monophosphate. It can be inhibited by ribonuclease inhibitor protein, by heavy metal ions, and by uridine-vanadate complexes.
Sources: en.wikipedia.org
Pseudouridine is an RNA modification that is introduced post-translationally, meaning after the RNA is transcribed. The proteins that facilitate this are called pseudouridine synthases (PUS) and are found in all kingdoms of life. Most research has been conducted on how PUS modify tRNA, so mechanisms involving snRNA and mRNA are not clearly defined. PUS can vary on RNA specificity, structure, and isomerization mechanisms. PUS enzymes are divided into five families which share an active sequence and important structural motifs.
is the initial condition. The first equation is the momentum balance equation, while the second represents the mass conservation, namely the continuity equation. Assuming constant dynamic viscosity, using the vectorial identity
The Maduro regime has violated all such principles in every respect. We stand for further developments in accordance with the principles of international law, prioritising democracy, human rights, and the interests of Venezuelans." Ukrainian President Volodymyr Zelenskyy reacted with a pointed remark to the United States' capture of Nicolás Maduro, suggesting the U.S. now "knows what to do next" when dealing with dictators. United Kingdom: Prime Minister Keir Starmer stated "The UK has long supported a transition of power in Venezuela. We regarded Maduro as an illegitimate President and we shed no tears about the end of his regime", adding "I always say and believe we should all uphold international law." He also clarified that the United Kingdom was not involved in the strikes. The Foreign Office advised against all travel to Venezuela for British citizens. South Ossetia: South Ossetia condemned the US attacks.
A substance (other than food) intended to affect the structure or any function of the body. A substance intended for use as a component of a medicine but not a device or a component, part, or accessory of a device. A substance intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. A substance recognized by an official pharmacopeia or formulary. Biological products are included within this definition and are generally covered by the same laws and regulations, but differences exist regarding their manufacturing processes (chemical process versus biological process).
==== Neutral loss scan ==== In the neutral loss scan method both Q1 and Q3 are scanned together, but with a constant mass offset. This allows the selective recognition of all ions which, by fragmentation in q2, lead to the loss of a given neutral fragment (e.g., H2O, NH3). Similar to the precursor ion scan, this method is useful in the selective identification of closely related compounds in a mixture.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.